Key statistics
As of last trade, Organon & Co (OGN:NYQ) traded at 7.30, 18.04% above the 52 week low of 6.18 set on Oct 30, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 7.02 |
|---|---|
| High | 7.35 |
| Low | 6.97 |
| Bid | 7.29 |
| Offer | 7.30 |
| Previous close | 7.06 |
| Average volume | 5.29m |
|---|---|
| Shares outstanding | 259.98m |
| Free float | 259.32m |
| P/E (TTM) | 3.67 |
| Market cap | 1.84bn USD |
| EPS (TTM) | 1.92 USD |
| Annual div (ADY) | 0.08 USD |
|---|---|
| Annual div yield (ADY) | 1.13% |
| Div ex-date | Nov 20 2025 |
| Div pay-date | Dec 11 2025 |
Data delayed at least 15 minutes, as of Feb 13 2026 19:02 GMT.
More ▼
- Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
- Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
- Organon Completes Divestiture of JADA® System to Laborie
- Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
- Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
- Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
- Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
More ▼
